Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nolato ABFRA:NBF +0.78%75 EV-to-EBITDA is 14.96 as of Aug. 22, 2026, which is 9% below its 10-year median of 16.48. GuruFocus rates FRA:NBF with a GF Score™ of 75/100 and a GF Value™ of €4.64 (Fairly Valued). The stock has 2 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Nolato AB ranks worse than 51.55% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nolato AB's enterprise value is €1,349.8 Mil.
Nolato AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €90.2 Mil. Therefore, Nolato AB's EV-to-EBITDA for today is 14.96.
The historical rank and industry rank for Nolato AB's EV-to-EBITDA or its related term are showing as below:
FRA:NBF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.97 Med: 16.48 Max: 24.09
Current: 15.13
During the past 13 years, the highest EV-to-EBITDA of Nolato AB was 24.09. The lowest was 8.97. And the median was 16.48.
FRA:NBF's EV-to-EBITDA is ranked worse than 51.55% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.7
vs FRA:NBF: 15.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nolato AB's share price for today is €4.525.
Nolato AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.243.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Nolato AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nolato AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nolato AB's EV-to-EBITDA falls into.
Nolato AB's current Enterprise Value is €1,349.8 Mil.
Nolato AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €90.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nolato AB (FRA:NBF) has a EV-to-EBITDA of 14.96 as of Aug. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nolato AB. This is near median its historical median of 16.48. Over the past decade, Nolato AB's EV-to-EBITDA has ranged from 8.97 to 24.09. According to the industry distribution chart, Nolato AB ranks #266 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 51.6%.
Is Nolato AB's EV-to-EBITDA too high?
Nolato AB's current EV-to-EBITDA of 14.96 is near median its 10-year median of 16.48. Over the past 10 years, this metric has ranged from a low of 8.97 to a high of 24.09. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.70. Nolato AB's value of 14.96 is 1.8% above this industry median. Based on the distribution chart, Nolato AB ranks #266 out of 516 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nolato AB has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #266 out of 516 companies for EV-to-EBITDA. This places Nolato AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.70. Nolato AB's value of 14.96 is 1.8% above this benchmark. Historically, Nolato AB's own EV-to-EBITDA has ranged from 8.97 to 24.09 over the past decade. While the company's 10-year median is 16.48 vs. the industry median of 14.70, Nolato AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.70, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nolato AB's current EV-to-EBITDA of 14.96 is 1.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nolato AB. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nolato AB's current EV-to-EBITDA is 14.96, which is near median its own 10-year median of 16.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Fairly Valued. The stock's GF Value™ is €4.64, compared to a current price of €4.53 — trading 2.5% below its estimated fair value. The current EV-to-EBITDA is 14.96, which is near median its 10-year median of 16.48 and 1.8% above the Medical Devices & Instruments industry median of 14.70. Nolato AB's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current EV-to-EBITDA is 14.96 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be undervalued.
The current stock price of €4.53 is trading 2.5% below its estimated GF Value™ of €4.64.
GuruFocus considers Nolato AB to be Fairly Valued.
Key valuation signals for FRA:NBF:
EV-to-EBITDA: 14.96 (near median its 10-year median of 16.48)
GF Value™: €4.64 vs. price of €4.53 (2.5% below fair value)
Industry Position: 1.8% above the Medical Devices & Instruments median (#266 of 516)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
75GF Score
Get the complete analysis for FRA:NBF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
